Skip to main content
Equibles

LPL Financial LLC

Position in SLS — SELLAS Life Sciences Group, Inc.

CIK 1403438 FORT MILL, SC
Back to SLS Full portfolio

Position in SLS

as of Jun 30, 2026 · filed Aug 7, 2026
Position Value
$2,297,585
+$1,717,196 QoQ
Shares Held
155,663
+13.5% QoQ
Ownership
0.077%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#40
of 192 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority Sole 0% Shared 0% None 100%

Common Shares in SLS Over Time

Shares Held

Position Value (USD)

Derivatives in SLS

reported options exposure · as of Dec 31, 2025
CallValue
$41,470
CallShares
11,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

LPL Financial LLC holds $557,763,742 across 203 Biotechnology names. SLS ranks #35 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 289,111 $143,610,107
2 REGN
Regeneron Pharmaceuticals, Inc.
 65,755 $41,000,872
3 ARWR
Arrowhead Pharmaceuticals, Inc.
 310,761 $25,330,129
4 ARGX
Argenx SE
 19,499 $18,090,587
5 ALNY
Alnylam Pharmaceuticals, Inc.
 57,890 $17,426,626
6 HALO
Halozyme Therapeutics, Inc.
 203,557 $15,932,406
7 RPRX
Royalty Pharma plc
 249,117 $13,967,990
8 INSM
INSMED Inc
 128,553 $13,706,320

All Filings in SLS

Export CSV
10 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $2,297,585 155,663
2026-03-31 $580,389 137,208
2025-12-31 $41,470 11,000
2025-12-31 $363,069 96,305
2025-09-30 $114,372 71,039
2025-06-30 $147,956 67,560
2025-03-31 $71,003 65,744
2024-12-31 $53,969 51,894
2024-09-30 $64,867 51,894
2024-06-30 $61,753 51,894